The Pennsylvania Biotechnology Center on Wednesday broke ground on a long-awaited expansion that will add laboratories, office space and at least 100 new jobs to its campus in Buckingham. "This has become a real state resource," said biotechnology center President Timothy Block. "We can't exist in these two buildings anymore. We need to grow." Because of the center's success, it's been a draw for scientists and entrepreneurs throughout the region. Lab space is at a premium, and there's a waiting list for tenants. The new wing is already 40 percent leased, Block said. The first tenant, contract research organization FlowMetric Inc., credits the center with its growth. The company now has three dozen employees. "I could have set up my company in New Jersey. But there was no place that was quite like this, and that has continued for us," said CEO Ren Capocasale. "This center is why I do what I do." While construction likely won't begin until the summer, biotech center officials chose Wednesday for the ceremonial groundbreaking in part because it also happened to be the 96th birthday of Joshua Feldstein, a longtime supporter for whom a wing of the center is named. Feldstein was on hand … Continue reading →

April 13, 2017 20:00 ET | Source: M3 Biotechnology SEATTLE, April 13, 2017 (GLOBE NEWSWIRE) -- As the first investor in M3 Biotechnology, the Alzheimers Drug Discovery Foundation (ADDF) helped validate the therapeutic potential of M3s drug candidate for Alzheimers disease. With a second investment of $1.4 million, the ADDF is now providing key funds to support the launch of human trials this year. While current drugs for Alzheimers disease only provide symptomatic relief, M3s small molecule therapeutics have the potential to be truly disease-modifying. By re-establishing lost connections between brain cells, these therapies may halt the course of the disease. M3 is now in the process of planning a first-in-humans Phase 1a clinical trial for its lead candidate, NDX-1017, to evaluate its safety and determine optimal dosing range. ADDFs first investment spurred others, including many private investors and Washington state-based venture groups W Fund and WRF Capital. These investments evidenced the faith in our potential, which helped us make it past the valley of death for drug development and raise nearly $14 million in additional funding, said Leen Kawas, M3s CEO. The most noteworthy new investor in M3 is Dolby Family Ventures, which invests in technology and life sciences. … Continue reading →

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Separation Systems for Commercial Biotechnology" report to their offering. The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a large-scale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research. The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, lab-on-a-chip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market. Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., Bio-Rad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others. Key Topics Covered: 1: Introduction 2: Summary and highlights 3: Overview - History of biotechnology - Classification of biomolecular separation systems in biotechnology - New methods of biomolecular separations - Molecular classes of biomolecular separation - End users of biotechnology separation systems 4: New Developments - Mergers and acquisitions 5: Market Analysis - Market by type - … Continue reading →